Mexico Alzheimers Disease Diagnostics Market Size & Outlook
Related Markets
Mexico alzheimers disease diagnostics market highlights
- The Mexico alzheimers disease diagnostics market generated a revenue of USD 149.0 million in 2025 and is expected to reach USD 334.0 million by 2033.
- The Mexico market is expected to grow at a CAGR of 10.7% from 2026 to 2033.
- In terms of segment, imaging techniques was the largest revenue generating diagnostic technique in 2025.
- Biomarkers is the most lucrative diagnostic technique segment registering the fastest growth during the forecast period.
Alzheimers disease diagnostics market data book summary
| Market revenue in 2025 | USD 149.0 million |
| Market revenue in 2033 | USD 334.0 million |
| Growth rate | 10.7% (CAGR from 2026 to 2033) |
| Largest segment | Imaging techniques |
| Fastest growing segment | Biomarkers |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests |
| Key market players worldwide | Quest Diagnostics Inc, Sysmex Corp, Lantheus Holdings Inc, Siemens Healthineers AG ADR, F. Hoffmann-La Roche Ltd., Quanterix, Fujirebio Diagnostics, C2N Diagnostics |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.6% of the global alzheimers disease diagnostics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. alzheimers disease diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 871.0 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Disease Diagnostics Market Scope
Alzheimers Disease Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Quanterix | View profile | 251-500 | Billerica, Massachusetts, United States, North America | http://www.quanterix.com |
| Fujirebio Diagnostics | View profile | 5001-10000 | Malvern, Pennsylvania, United States, North America | http://www.fdi.com/ |
| C2N Diagnostics | View profile | 11-50 | Saint Louis, Missouri, United States, North America | https://c2n.com/ |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Lantheus Holdings Inc | View profile | 834 | 201 Burlington Road, South Building, Bedford, MA, United States, 01730 | https://www.lantheus.com |
| Sysmex Corp | View profile | 10448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | http://www.sysmex.co.jp |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
| Siemens Healthineers AG ADR | View profile | 71400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | https://www.siemens-healthineers.com |
Mexico alzheimers disease diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers disease diagnostics market will help companies and investors design strategic landscapes.
Imaging techniques was the largest segment with a revenue share of 44.56% in 2025. Horizon Databook has segmented the Mexico alzheimers disease diagnostics market based on biomarkers, imaging techniques, genetic testing, cognitive assessment tests covering the revenue growth of each sub-segment from 2021 to 2033.
The increasing awareness about public health and early diagnosis, demographic shifts, and governmental support are driving the market in Mexico. For instance, according to an article published by Eisai Inc, in December 2024, it is estimated that 1.3 million people in Mexico have Alzheimer's disease, which makes up 60–70% of all dementia diagnoses.
People over 65 are most typically affected by Alzheimer's disease. Moreover, strategic initiatives by key market players such as product approval, partnership, and others help in strengthening the market growth. For instance, in December 2024, COFEPRIS approved LEQEMBI, a humanized monoclonal antibody developed by Eisai and Biogen, for the treatment of early-stage AD.
LEQEMBI targets and reduces amyloid-beta protofibrils and plaques in the brain, which are key contributors to AD progression. This approval was based on positive results from the global Phase 3 Clarity AD study, marking a significant advancement in AD treatment options in Mexico.
Reasons to subscribe to Mexico alzheimers disease diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico alzheimers disease diagnostics market databook
-
Our clientele includes a mix of alzheimers disease diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico alzheimers disease diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico alzheimers disease diagnostics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico alzheimers disease diagnostics market size, by diagnostic technique, 2021-2033 (US$M)
Mexico Alzheimers Disease Diagnostics Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
